S. 2198 · 118th Congress (2023–2025)
Prescription Drug Supply Chain Pricing Transparency Act
A bill to require the Comptroller General of the United States to conduct a study and submit a report on price-related compensation and payment structures in the prescription drug supply chain.
CRS summary not yet available.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to committee
This bill’s path
This is S. 2198’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Michael F. Bennet (D-CO)
- Cosponsors
1 cosponsor
1 original · 0 later
- Sen. James Lankford (R-OK)· Original · Jun 22, 2023
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
Referred to committee
Read twice and referred to the Committee on Finance.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Referred to Senate Finance → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in Senate |
Titles (2)
Prescription Drug Supply Chain Pricing Transparency Act
Display title, Short title · Introduced in Senate
A bill to require the Comptroller General of the United States to conduct a study and submit a report on price-related compensation and payment structures in the prescription drug supply chain.
Official title · Introduced in Senate